Dr Stephen Mullin
Clinical Lectureship In Neurology
Peninsula Medical School (Faculty of Health: Medicine, Dentistry and Human Sciences)
I am a neurologist and clinical academic with a research interest in Parkinson disease. My primary interest is the genetic and clinical stratification of the risk of Parkinson disease for targeting of novel neuroprotective compounds. I also have expertise in clinical trial design and implementation and internet based clinical assessment in Parkinson disease. To date the majority of my research has centered on the glucocerebrosidase (GBA) pathway, numerically the most significant genetic risk factor for Parkinson disease. This included the day to day running of a phase II clinical trial of ambroxol, a putative neuroprotective and small molecular chaperone of the glucocerebrosidase enzyme (GCase). Additionally I jointly run an internet based cohort study, Rapsodi, which aims to stratify GBA mutations carriers without Parkinson disease in terms of their disease risk using clinical, genetic and biochemical parameters. The ultimate of this study is to provide a cost effective platform for targeting of future neuroprotective compounds.
BSc. Medical Sciences, University College London, 2006.
MBBS. Medicine, Imperial College London, 2008.
MRCP, Royal College of Physicians, 2012 .
Molecular Neurology and Therapeutics course, Wellcome Trust, 2014.
Advanced course is epidemiology and statistics, London School of Hygiene and Tropical Medicine, 2017.
PhD. Neuroscience, University College London, 2018
Specialty Certificate Examination in Neurology, Royal College of Physicians, 2019
Key publications are highlightedJournals
Reports & invited lectures
High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania World Congress of Neurology November 2012, Marrakesh
Seeing the wood through the trees: Which GBA mutation carriers get Parkinson’s disease, when and why? Leonard Wolfson annual neurodegeneration symposium London, February 2016
Gaucher and Parkinson’s disease: Questions and opportunities. European Society of Lysosomal storage diseases, Vienna, October 2016
GBA Parkinson’s: a prototype for targeted neuroprotection in idiopathic Parkinson’s disease Parkinson’s UK annual conference, Leeds, November 2016
Novel therapeutic approaches in GBA PD, Italian Society of Neuroscience annual meeting, Ischia, Italy, October 2017